Recently, Changzhou Science and Education City and Beijing Dandelion Robot Technology Co., Ltd., a leading company in China's rehabilitation robot industry, signed a strategic cooperation agreement in Beijing to jointly launch the research and development and industrialization project of a multimodal rehabilitation data intelligent platform system. Dandelion Robot is a leading provider of authoritative exoskeleton robot treatment solutions in China and a pioneer in continuous original research and development in the rehabilitation robot field, establishing an innovative clinical research direction for the domestic exoskeleton rehabilitation robot industry. The signed project will integrate advanced sensors, artificial intelligence algorithms, and exoskeleton robot technologies to develop a comprehensive rehabilitation system that combines precise evaluation, intelligent training planning, real-time feedback, and effect tracking.

Recently, "Zhongke Medical Valley," a one-stop, full-chain medical innovation and transformation service complex, was officially inaugurated in Hefei, Anhui. This is a medical technology achievement transformation service platform based on the "hospital + government + capital" model, marking an important breakthrough in the construction of Anhui Province's collaborative innovation ecosystem involving "government, medicine, industry, academia, research, and capital." "Zhongke Medical Valley" will focus on the medical device industry sector, aiming to build a full-chain medical technology achievement transformation platform that integrates key links such as technical对接, technical consulting, professional training, concept verification, achievement roadshows, technology transfer, scenario applications, business incubation, and investment and financing. "Zhongke Medical Valley" is supported by the First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) for clinical innovation achievements and transformation, strengthened by the Luyang District People's Government of Hefei City in terms of policy and carrier guarantees, and coordinated by Hefei Industrial Investment Holding (Group) Co., Ltd. for capital对接and scientific innovation services.

Recently, Scienheart announced that its holding subsidiary, Scienheart Neurovascular Technology Co., Ltd., has received notification from the U.S. Food and Drug Administration (FDA) that the COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, independently developed by its holding subsidiary Scienheart Neurovascular, have been granted FDA Breakthrough Device Designation. These products, which are designed for the treatment of intracranial atherosclerotic stenosis, represent the first Chinese-produced neurointerventional devices to receive this FDA designation. The achievement marks another significant milestone in Scienheart's strategic progress toward innovative ischemic stroke treatment solutions. It highlights the technological innovation and substantial clinical advantages of the COMETIU self-expanding intracranial drug-coated stent system, which have been further recognized by an authoritative international regulatory body. This product fills a global gap in the treatment of intracranial atherosclerotic stenosis and, as a breakthrough medical technology, will bring new hope of recovery to millions of stroke patients worldwide.

Recently, at the 31st China International Medical Equipment Exhibition, Neusoft Medical showcased revolutionary innovative products and solutions, including the NeuViz P10 Wide-body Photon Counting CT. As China’s first domestically produced photon counting CT to enter the National Medical Products Administration's special review process for innovative medical devices, the NeuViz P10 utilizes cadmium zinc telluride (CZT) semiconductor material and a wide-body detector design, achieving breakthroughs in high spatial resolution, low radiation dose, and multi-energy imaging. This will bring significant advancements in the early and precise diagnosis of major diseases such as cardiovascular conditions and cancer. Currently, the NeuViz P10 Wide-body Photon Counting CT has been installed in several top-tier hospitals and has entered the substantive clinical validation phase, with expectations to gain approval for market release within the year.

On August 21, Angel Dental and Yake Wisdom held a delivery launch event for the dental surgery robot in Nanning, jointly exploring the application prospects of smart healthcare in the dental field. The launch event announced the official commissioning of the "Yake Wisdom Dental Surgery Robot," marking a new phase of intelligent development in dental healthcare in Guangxi, showcasing Yake Wisdom's technical strength and service capabilities as a leader in dental surgery robots in China.

On August 18, Orient Gene Biotech announced that the company and its wholly-owned subsidiaries, U.S.-based Healgen Scientific and Shanghai Wanzijian Biotechnology, had recently obtained multiple medical device registration certificates. The domestic registrations include the Influenza A/B Virus Antigen Test Kit (Colloidal Gold Method) (Professional Use) and test kits for anti-myeloperoxidase antibodies, anti-proteinase 3 antibodies, and anti-glomerular basement membrane antibodies (Flow Fluorescence Immunoassay Method). Overseas registrations include the Healgen® Immunofluorescence Analyzer (OG-H180) and the Healgen® AccuFluor Fentanyl Fluorescence Immunoassay (FIA) Test Kit - Qualitative. The acquisition of these certificates will expand the company’s product portfolio and enhance market competitiveness.

Recently, the official website of the National Healthcare Security Administration released the "Pricing Guidelines for Physical Therapy Medical Services (Trial)", standardizing the pricing system for physical therapy services. Previously, the National Healthcare Security Administration had issued a series of pricing guidelines for medical services, unifying and standardizing key pricing elements of medical service items nationwide. Reportedly, this "Guideline" breaks away from the traditional approach of pricing based on specific technical projects, shifting towards a new model "oriented towards service output, separating technical labor from material consumption". Additionally, it empowers innovative original technologies like the Kangbo Knife Composite Cryoablation at the guideline level. This shift not only reflects the value of medical services more scientifically and precisely but also removes pricing mechanism barriers for the faster implementation and application of innovative medical devices, marking a new phase of scientific and meticulous management in medical service pricing mechanisms.

Recently, the results of a general radiography equipment centralized procurement project in Chongqing, with a budget of nearly 109 million yuan, were announced. This centralized procurement covered 154 sets of imaging equipment, including 139 sets of DR equipment, 10 C-arm machines, and 4 gastro-intestinal machines. All equipment required a minimum warranty period of five years. The final winning bid was only 39.183 million yuan, significantly lower than the budget. Among them, Wiseking won bids for 140 devices at a total amount of 35.863 million yuan; Xinhua Medical, Lanying, and Neusoft Medical won bids for 6, 4, and 4 devices respectively. In Lot 3, Wiseking's MTX980A won the bid at a total price of 4.68 million yuan, compared to a budgeted total price of 17.19 million yuan, achieving a cost-saving rate of up to 72.77%. In Lot 2, Wiseking’s dynamic DR won the bid at a total price of 14.679 million yuan, decreasing by 60.97% from the budgeted total price of 37.6047 million yuan.

Recently, in accordance with the relevant requirements of the Beijing-Tianjin-Hebei "3+N" Alliance Provincial Alliance for orthopedic trauma medical devices and the Beijing-Tianjin-Hebei "3+N" Alliance Medical Device Group Purchasing, the first procurement year agreement in our province has expired. The Jiangxi Provincial Medical Insurance Bureau has issued a notice regarding the signing of the second procurement year agreement. The second-year procurement agreement period will be from August 1, 2025, to July 31, 2026. According to the relevant requirements of the "Provincial Alliance Orthopedic Trauma Medical Devices Centralized Volume-based Procurement Document (LH-HD2023-12)," the Jiangxi Provincial Medical Insurance Bureau has organized medical institutions in Jiangxi Province to complete the demand volume reporting for the second year. The Jiangxi Provincial Medical Insurance Bureau will no longer centrally organize the selected enterprises to adjust distribution relationships. Based on the needs of medical institutions and market supply and demand, the selected enterprises can independently adjust the distribution enterprises of the selected products in various regions through the procurement subsystem. Medical institutions should ensure smooth channels for the entry of selected products into hospitals, complete the agreed procurement volume on time, and based on prioritizing the procurement of selected products, appropriately purchase other high-quality and reasonably priced medical devices of the same type according to clinical rational use.

Recently, the 2025 Xipu Conference (China Health Industry Ecosystem Conference) was held in Boao, Hainan. During the conference, Fu Sheng, Director of the Administration Bureau of Boao Lecheng International Medical Tourism Pilot Zone in Hainan, introduced that Lecheng is a national experimental ground for reform and opening-up in the healthcare sector. As a medical special zone, Lecheng enjoys innovative policies that are open across China, including special medical treatment, special research, special operation, and special international medical exchange. Currently, it has enabled the use of over 500 international innovative medical devices and 10 types of special food from overseas in China, benefiting more than 160,000 patients. It takes the lead in opening up clinical transformation and application of new biotechnologies such as cell therapy and gene therapy nationwide, successfully implementing eight cutting-edge innovation projects. Lecheng is becoming a gathering place for global medical innovation achievements and a city of hope that safeguards the light of life for patients.

Recently, the General Office of the People's Government of Hainan Province issued the "Several Policy Measures of Hainan Province to Further Support the High-Quality Development of the Biopharmaceutical Industry." The policy measures propose to continuously increase support for the research and development of innovative drugs and medical devices. The provincial biopharmaceutical industry R&D voucher policy will continue to be implemented, providing financial rewards ranging from 400,000 to 10 million yuan for the entire process of product development, including preclinical research, clinical trials, and new achievements industrialization, based on phased results. The policy measures also propose to encourage enterprises within and outside the province to legally merge and restructure pharmaceutical enterprises in Hainan, revitalize assets locally, and grow stronger. A 50% interest subsidy will be provided for bank loans incurred in mergers and acquisitions, with continuous subsidies for two years, up to a maximum of 5 million yuan. Enterprises are encouraged to obtain international certifications, and pharmaceutical and medical device enterprises that receive authoritative international certifications will be granted a one-time reward of 2 million yuan according to regulations.

Recently, the celebration of the eighth Chinese Physicians' Day and the release event of core medical technologies was held at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan, Hubei Province. A total of 112 core medical technology achievements were announced on-site. Among the 112 technologies, 32 are leading technologies, including the "Chen's Pancreaticojejunostomy" technique, "Micro Life Pump" technology, and myocardial rotary cutting technology that allows for non-thoracotomy procedures; 40 are pioneering technologies, such as component corneal transplantation that enables one donated cornea to treat three patients, "Bionic Multi-Organ Chip" technology that can replace live drug testing, and 3D printing technology capable of "reviving" damaged tissues; and 40 are foundational strengthening technologies, including the "Super Minimally Invasive" immediate stone removal technology that spares patients from secondary surgeries, endoscopic-assisted continuous negative pressure suction for gastrointestinal fistulas that clinicians can master after short-term training, and precision interventional reperfusion technology for acute ischemic stroke that has been extended to grassroots hospitals.

Recently, the Guizhou Provincial Drug Administration issued the "Implementation Opinions of the Provincial Drug Administration on Implementing the Announcement of the National Medical Products Administration on Optimizing Full-Life Cycle Supervision to Support Innovation and Development of High-End Medical Devices." First, strengthen technical support and accelerate the transformation of scientific research results. By establishing a "project list," eligible high-end medical device projects will be managed through a checklist system. Coordinate with qualified medical device clinical trial institutions within the province to prioritize clinical trials, focusing on advancing the clinical trial process and promptly helping enterprises solve difficult issues encountered during clinical trials. Second, optimize service mechanisms and improve the efficiency of approval services. Leverage the role of the Provincial Drug Administration's pharmaceutical industry development front-line service task force by forming an expert team to provide "one-on-one" guidance for high-end medical devices included in the NMPA's special approval process before registration applications. This covers the entire chain of services from factory construction, registration document preparation to quality management system establishment. A "green channel" will be opened for high-end medical device products, striving to reduce testing cycles to 80% of the agreed time where testing conditions permit, shortening the time to market for products.